Effects of Long-Term Treatment with Human Recombinant Erythropoietin in Patients on CAPD
-
Published:1989
Issue:
Volume:
Page:157-165
-
ISSN:0065-2598
-
Container-title:New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmapheresis
-
language:
-
Short-container-title:
Author:
Steinhauer Hjalmar B.
Reference23 articles.
1. Eschbach, J.W., Adamson, J.W.:Anemia of end-stage renal disease (ESRD). Kidney Int. 28:1 (1985). 2. Winearls, C.G., Oliver, D.O., Pippard, M.J., Reid, C., Downing, M.R., Cotes, P.M.: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic hemodialysis. Lancet ii:1175 (1986). 3. Eschbach, J.W., Egrie, J.C., Downing, M.R., Browne, J.K., Adamson, J.W.: Correction of the anaemia of end-stage renal disease with recombinant human erythropoietin: Results of the phase I and II clinical trial. New Engl. J. Med. 316:73 (1987) . 4. Bommer, J., Alexiou, C., Müller-Bühl, E., Eifert, J., Ritz, E.: Recombinant human erythropoietin therapy in hemodialysis patients — dose determination and clinical experience. Nephrol. Dial. Transplant. 2:238 (1987). 5. Casati, S., Passerini, P., Campise, M.R., Graziani, G. , Cesana, B., Perisic, M., Ponticelli, C.: Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br. med. J. 295:1017 (1987).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|